Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat

March 4, 2021 7:36 AM EST

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.62), $0.12 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $2.7 million.

2021 promises to be a pivotal year for Syros, said Nancy Simonian, M.D., Chief... More